SenzaGen and AstraZeneca initiate technology development collaboration
SenzaGen has signed a collaboration agreement with the global biopharmaceutical company AstraZeneca. The collaboration focuses on testing and development of SenzaGen's sensitization test GARDair, in order to distinguish between allergens and irritants in the respiratory tract. The goal is the validation of in vitro toxicological tests that could be applied to the discovery of new treatments for respiratory diseases without respiratory tract irritancy as a side effect.The collaboration means that SenzaGen will use its leading technology platform GARD, with the help of AstraZeneca's well-